0.4205SEK+3.83%Mkt Cap: 70.58M SEKP/E: —Last update: 2026-05-13
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheime…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.76
PEG—
P/B0.39
P/S2.75
EV/EBITDA—
EV/Revenue1.44
EPS (TTM)-0.25
EPS (Forward)-0.60
Cash Flow & Leverage
FCF Yield-55.96%
FCF Margin-153.96%
Operating CF-13.03M SEK
CapEx (TTM)26.55M SEK
Net Debt/EBITDA—
Net Debt-10.58M SEK
Technical
SMA 500.5617 (-25.1%)
SMA 2001.032 (-59.3%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)877.52K
Avg Vol (10d)903.61K
Technical Indicators
RSI (14)32.2
MACD-0.0504
MACD Signal-0.0494
MACD Hist.-0.0010
BB Upper0.6183 SEK
BB Middle0.4787 SEK
BB Lower0.3391 SEK
BB Width58.34%
ATR (14)0.0429 SEK
Vol Ratio (20d)0.45x
52W Range
0.38602% of range2.280
52W High2.280 SEK
52W Low0.3860 SEK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-103.58%
Oper. Margin-99.01%
ROE-21.54%
ROA-18.31%
Revenue Growth-18.80%
Earnings Growth—
Balance Sheet
Debt/Equity0.01
Current Ratio1.37
Quick Ratio1.33
Book Value/Sh1.169 SEK
Cash/Share0.1090 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.154.96M
Float83.46M
Insiders17.77%
Institutions8.62%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)2.300 SEK
Target Range2.000 SEK – 2.600 SEK
# Analysts2
Company
Market Cap70.58M SEK
Enterprise Value36.94M SEK
Revenue (TTM)25.66M SEK
Gross Profit26.55M SEK
Net Income (TTM)-26.27M SEK
Revenue/Share0.2730 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
Last Price0.4205 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—